PD Dr. Markus Eckstein

Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Institute of Pathology

Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial (2024) Vitali F, Merkel S, Schubart C, Schmid A, Eckstein M, Stöhr R, Kersting S, et al. Journal article Digital volumetric assessment of CIS and tumor mass compliments conventional histopathological assessment in muscle-invasive urothelial bladder cancer (2024) Lange F, Geppert CI, Bahlinger V, Bertz S, Stöhr R, Sikic D, Taubert H, et al. Journal article An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer (2024) Reike MJ, Reicherz A, Tully KH, Bahlburg H, Maas M, Bach P, Klümper N, et al. Journal article On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy. (2024) Saal J, Grünwald V, Bald T, Ritter M, Brossart P, Tomita Y, Hartmann A, et al. Journal article Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC Monitor (2024) Haas M, Kriegmair MC, Breyer J, Sikic D, Wezel F, Roghmann F, Brehmer M, et al. Journal article Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer (2024) Klümper N, Eckstein M Journal article, Review article Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer (2024) Klümper N, Vera-Badillo FE, Eckstein M, Hadaschik B, Grünwald V Journal article A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer (2024) Haas M, Engelmann SU, Mayr R, Gossler C, Pickl C, Kälble S, Yang Y, et al. Journal article Diagnosis of malignancy in oropharyngeal confocal laser endomicroscopy using GPT 4.0 with vision (2024) Sievert M, Aubreville M, Müller SK, Eckstein M, Breininger K, Iro H, Goncalves M Journal article Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts (2024) Bahlinger V, Branz A, Strissel P, Strick R, Lange F, Geppert CI, Klümper N, et al. Journal article